Puerto Rico facility supplements Abraxis’ capabilities to support expansion of its injectables portfolio.
Abraxis BioScienc finalized the acquisition of the Pfizer Cruce Dávila manufacturing facility in Barceloneta, Puerto Rico. This 56-acre site consists of a 172,000-sq-ft plant with capabilities of producing injectable pharmaceuticals as well as protein-based biologics and metered-dosed inhalers, according to Abraxis.
In addition, the acquisition includes a computer-controlled 90,000-sq-ft active pharmaceutical ingredients manufacturing plant and two support facilities with quality assurance and laboratories.
Under the terms of the agreement, Abraxis will lease the active pharmaceuticals ingredients plant back to Pfizer. Abraxis expects to begin commercial manufacturing from this site in the first half of 2007.
